FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 3355人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839982, encodeId=9f4a18399826f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=君实生物JS110（XPO1抑制剂）临床试验申请获得美国FDA批准, objectType=article, longId=737116, objectId=19f3e3711610, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f3e3711610, replyNumber=0, likeNumber=45, createdTime=2023-01-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f3e3711610, moduleTitle=君实生物JS110（XPO1抑制剂）临床试验申请获得美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19f3e3711610)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839981, encodeId=0a421839981a6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=60年来首次！FDA批准重度抑郁口服速效药物Auvelity（右美沙芬与安非他酮缓释复方制剂），1周起效！, objectType=article, longId=736474, objectId=0ecce36474e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ecce36474e6, replyNumber=0, likeNumber=60, createdTime=2023-01-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ecce36474e6, moduleTitle=60年来首次！FDA批准重度抑郁口服速效药物Auvelity（右美沙芬与安非他酮缓释复方制剂），1周起效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ecce36474e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839985, encodeId=85471839985c0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准降解Myc的分子胶药物MRT-2359进入临床试验, objectType=article, longId=738460, objectId=9619e3846026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9619e3846026, replyNumber=0, likeNumber=67, createdTime=2023-04-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9619e3846026, moduleTitle=FDA批准降解Myc的分子胶药物MRT-2359进入临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9619e3846026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839971, encodeId=945618399e172, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=内布拉斯加大学医学中心和阿南达宣布，FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验, objectType=article, longId=727294, objectId=7dfee27294b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dfee27294b1, replyNumber=0, likeNumber=59, createdTime=2023-03-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dfee27294b1, moduleTitle=内布拉斯加大学医学中心和阿南达宣布，FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dfee27294b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839967, encodeId=1936183996eaf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=盘点2017-2021年美国FDA批准的抗肿瘤新药, objectType=article, longId=725295, objectId=38cde25295d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38cde25295d6, replyNumber=0, likeNumber=51, createdTime=2022-09-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38cde25295d6, moduleTitle=盘点2017-2021年美国FDA批准的抗肿瘤新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38cde25295d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839960, encodeId=1f53183996043, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症, objectType=article, longId=301200, objectId=5b2c3012001e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b2c3012001e, replyNumber=0, likeNumber=46, createdTime=2022-03-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b2c3012001e, moduleTitle=FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b2c3012001e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839963, encodeId=28931839963b7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准放射性配体疗法Pluvicto治疗前列腺癌, objectType=article, longId=301806, objectId=2e2e30180675, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e2e30180675, replyNumber=0, likeNumber=60, createdTime=2022-05-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e2e30180675, moduleTitle=FDA批准放射性配体疗法Pluvicto治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e2e30180675)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839977, encodeId=405d18399e742, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=NEJM：可恢复80%头发生长，FDA批准首款口服抗脱发新药上市, objectType=article, longId=729601, objectId=94b7e29601db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b7e29601db, replyNumber=0, likeNumber=59, createdTime=2022-12-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b7e29601db, moduleTitle=NEJM：可恢复80%头发生长，FDA批准首款口服抗脱发新药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b7e29601db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839970, encodeId=721218399e0e1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准双靶向2型糖尿病药物Mounjaro，它能帮助非糖尿病患者减重22.5%！, objectType=article, longId=727036, objectId=c4dfe27036c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4dfe27036c6, replyNumber=0, likeNumber=48, createdTime=2022-12-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4dfe27036c6, moduleTitle=FDA批准双靶向2型糖尿病药物Mounjaro，它能帮助非糖尿病患者减重22.5%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4dfe27036c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839969, encodeId=2bde1839969cf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, objectType=article, longId=725731, objectId=7110e25731dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7110e25731dc, replyNumber=0, likeNumber=51, createdTime=2023-01-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7110e25731dc, moduleTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7110e25731dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839973, encodeId=f02c18399e366, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准非药物疗法NeuroMetrix治疗纤维肌痛，是一种创新神经调节医疗器械, objectType=article, longId=729774, objectId=849ee29774d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849ee29774d3, replyNumber=0, likeNumber=59, createdTime=2022-11-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849ee29774d3, moduleTitle=FDA批准非药物疗法NeuroMetrix治疗纤维肌痛，是一种创新神经调节医疗器械, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849ee29774d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839955, encodeId=28561839955de, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔, objectType=article, longId=295514, objectId=81472955144d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81472955144d, replyNumber=0, likeNumber=44, createdTime=2023-01-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81472955144d, moduleTitle=2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81472955144d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839952, encodeId=75a9183995211, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准HIV药物Cabenuva更长的给药间隔, objectType=article, longId=295077, objectId=c48d2950e75b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48d2950e75b, replyNumber=0, likeNumber=46, createdTime=2022-08-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48d2950e75b, moduleTitle=FDA批准HIV药物Cabenuva更长的给药间隔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48d2950e75b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839954, encodeId=02ec1839954a6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准赛诺菲的Enjaymo治疗冷凝集素病, objectType=article, longId=295168, objectId=2c1b295168db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c1b295168db, replyNumber=0, likeNumber=44, createdTime=2022-04-16, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c1b295168db, moduleTitle=FDA批准赛诺菲的Enjaymo治疗冷凝集素病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c1b295168db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839957, encodeId=e12e183995e30, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市, objectType=article, longId=299876, objectId=e4402998e658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4402998e658, replyNumber=0, likeNumber=57, createdTime=2022-05-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4402998e658, moduleTitle=FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4402998e658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839956, encodeId=d2451839956b0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Pyrukynd治疗成人溶血性贫血, objectType=article, longId=299148, objectId=b3a1299148a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3a1299148a2, replyNumber=0, likeNumber=48, createdTime=2023-01-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3a1299148a2, moduleTitle=FDA批准Pyrukynd治疗成人溶血性贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3a1299148a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839972, encodeId=c47a18399e2cf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=25年来首次！FDA批准银屑病外用新药上市——本维莫德乳膏, objectType=article, longId=727833, objectId=2359e27833d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2359e27833d5, replyNumber=0, likeNumber=57, createdTime=2022-06-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2359e27833d5, moduleTitle=25年来首次！FDA批准银屑病外用新药上市——本维莫德乳膏, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2359e27833d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839964, encodeId=6ed51839964ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2022年3月30日简报：上海新增本土病例326+5656；FDA批准特定人群接种第二剂新冠疫苗加强针；以色列研究发现4针疫苗可将老年人死亡率降低78%；, objectType=article, longId=302010, objectId=a5603020107c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5603020107c, replyNumber=0, likeNumber=41, createdTime=2022-07-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5603020107c, moduleTitle=2022年3月30日简报：上海新增本土病例326+5656；FDA批准特定人群接种第二剂新冠疫苗加强针；以色列研究发现4针疫苗可将老年人死亡率降低78%；, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5603020107c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839984, encodeId=7585183998489, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, objectType=article, longId=737420, objectId=555de3742013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555de3742013, replyNumber=0, likeNumber=0, createdTime=2022-10-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555de3742013, moduleTitle=百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555de3742013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839975, encodeId=e47f18399e563, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准用于多发性硬化的外骨骼机器人, objectType=article, longId=729776, objectId=c4b3e29776fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4b3e29776fd, replyNumber=0, likeNumber=54, createdTime=2022-10-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4b3e29776fd, moduleTitle=FDA批准用于多发性硬化的外骨骼机器人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4b3e29776fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

君实生物JS110（XPO1抑制剂）临床试验申请获得美国FDA批准

2023-01-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

60年来首次！FDA批准重度抑郁口服速效药物Auvelity（右美沙芬与安非他酮缓释复方制剂），1周起效！

2023-01-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准降解Myc的分子胶药物MRT-2359进入临床试验

2023-04-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

内布拉斯加大学医学中心和阿南达宣布，FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验

2023-03-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

盘点2017-2021年美国FDA批准的抗肿瘤新药

2022-09-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症

2022-03-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准放射性配体疗法Pluvicto治疗前列腺癌

2022-05-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

NEJM：可恢复80%头发生长，FDA批准首款口服抗脱发新药上市

2022-12-20

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准双靶向2型糖尿病药物Mounjaro，它能帮助非糖尿病患者减重22.5%！

2022-12-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准

2023-01-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准非药物疗法NeuroMetrix治疗纤维肌痛，是一种创新神经调节医疗器械

2022-11-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2022年2月12日简报：FDA批准首款针对奥密克戎的新抗体药物；意大利取消户外口罩令；英国政府科学家：奥密克戎是个例外，下一个变异毒株或类似德尔塔

2023-01-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准HIV药物Cabenuva更长的给药间隔

2022-08-03

仁医06 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准赛诺菲的Enjaymo治疗冷凝集素病

2022-04-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市

2022-05-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Pyrukynd治疗成人溶血性贫血

2023-01-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

25年来首次！FDA批准银屑病外用新药上市——本维莫德乳膏

2022-06-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2022年3月30日简报：上海新增本土病例326+5656；FDA批准特定人群接种第二剂新冠疫苗加强针；以色列研究发现4针疫苗可将老年人死亡率降低78%；

2022-07-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

百奥赛图与TRACON共同宣布YH001（CTLA-4单抗）联合恩沃利单抗（PD-L1）一线治疗软组织肉瘤的临床试验申请获得FDA批准

2022-10-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准用于多发性硬化的外骨骼机器人

2022-10-25

科室
- - 订阅+
  - 更多科室
工具
服务